A comparison between phase-III trials and a phase-IV study of nalmefene in alcohol use disorder patients. Is there a difference?
DOI:
https://doi.org/10.20882/adicciones.1046Keywords:
Phase-III trial, Phase-IV trial, External validity, Nalmefene, Alcohol use disordersAbstract
Concerns regarding the external validity of phase-III trials are common to many medical disciplines, with relevant discrepancies found between experimental and clinical samples in some diseases such as hypertension. The aim of this study was to compare the samples included in the pivotal, phase-III clinical trials of nalmefene with that of a recently conducted phase-IV trial. Baseline characteristics of the studies were compared through univariate analysis. Significant differences were found in the percentage of low-risk drinkers included. Differences were also found in the prescription and intake pattern of nalmefene, as well as in the rate of psychiatric and addictive comorbidities, which were much higher in the phase-IV study. These data suggest that in the field of alcohol use disorders there are also relevant differences between experimental and clinical samples, a fact that reinforces the need for phase-III trials to be balanced with observational, phase-IV trials.References
Barrio, P., Ortega, L., Guardia, J., Roncero, C., Yuguero, L. y Gual, A. (2018). Who Receives Nalmefene and How Does It Work in the Real World? A Single-Arm, Phase IV Study of Nalmefene in Alcohol Dependent Outpatients: Baseline and 1-Month Results. Clinical Drug Investigation, 38, 147-155. doi:10.1007/s40261-017-0590-4.
Dekkers, O. M., von Elm, E., Algra, A., Romijn, J. A. y Vandenbroucke, J. P. (2010). How to assess the external validity of therapeutic trials: a conceptual approach. International Journal of Epidemiology, 39, 89–94. doi:10.1093/ije/dyp174.
Farahani, P., Levine, M., Gaebel, K. y Thabane, L. (2005). Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis. The Canadian Journal of Clinical Pharmacology, 12, e254-263.
Fein, G. (2015). Psychiatric Comorbidity in Alcohol Dependence. Neuropsychology Review, 25, 456–475. doi:10.1007/s11065-015-9304-y.
Flensborg-Madsen, T., Mortensen, E. L., Knop, J., Becker, U., Sher, L. y Grønbæk, M. (2009). Comorbidity and temporal ordering of alcohol use disorders and other psychiatric disorders: results from a Danish register-based study. Comprehensive Psychiatry, 50, 307–314. doi:10.1016/j.comppsych.2008.09.003.
Gual, A., He, Y., Torup, L., van den Brink, W., Mann, K. y ESENSE 2 Study Group. (2013). A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. European Neuropsychopharmacology, 23, 1432–1442. doi:10.1016/j.euroneuro.2013.02.006.
Hoertel, N., de Maricourt, P., Katz, J., Doukhan, R., Lavaud, P., Peyre, H. y Limosin, F. (2014). Are participants in pharmacological and psychotherapy treatment trials for social anxiety disorder representative of patients in real-life settings? Journal of Clinical Psychopharmacology, 34, 697–703. doi:10.1097/JCP.0000000000000204.
Linden, M. (1984). Phase-IV Research: Specifics, Objectives and Methodology. Pharmacopsychiatry, 17, 140–142. doi:10.1055/s-2007-1017425.
Mann, K., Bladström, A., Torup, L., Gual, A. y van den Brink, W. (2013). Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biological Psychiatry, 73, 706–713. doi:10.1016/j.biopsych.2012.10.020.
Pearson, M. y Coomber, R. (2010). The challenge of external validity in policy-relevant systematic reviews: a case study from the field of substance misuse. Addiction, 105, 136–145. doi:10.1111/j.1360-0443.2009.02713.x.
Persaud, N. y Mamdani, M. M. (2006). External validity: the neglected dimension in evidence ranking. Journal of Evaluation in Clinical Practice, 12, 450–453. doi:10.1111/j.1365-2753.2006.00730.x.
Rothwell, P. M. (2005). External validity of randomised controlled trials: “to whom do the results of this trial apply?”. Lancet, 365, 82–93. doi:10.1016/S0140-6736(04)17670-8.
Uijen, A. A., Bakx, J. C., Mokkink, H. G. A. y van Weel, C. (2007). Hypertension patients participating in trials differ in many aspects from patients treated in general practices. Journal of Clinical Epidemiology, 60, 330–335. doi:10.1016/j.jclinepi.2006.05.015.
van den Brink, W., Aubin, H. J., Bladstrom, A., Torup, L., Gual, A. y Mann, K. (2013). Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies. Alcohol and Alcoholism, 48, 570–578. doi:10.1093/alcalc/agt061.
van den Brink, W., Sørensen, P., Torup, L., Mann, K., Gual, A. y SENSE Study Group. (2014). Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study. Journal of Psychopharmacology, 28, 733–744. doi:10.1177/0269881114527362.
Whiteford, H. A., Degenhardt, L., Rehm, J., Baxter, A. J., Ferrari, A. J., Erskine, H. E.,… Vos, T. (2013). Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet, 382, 1575–1586. doi:10.1016/S0140-6736(13)61611-6.
